RapidAI, a leading global company focused on developing Artificial Intelligence (AI) and technology workflow solutions to combat life-threatening neurovascular, cardiac, and vascular diseases, has announced a significant milestone in its growth journey. The company has secured $75 million in Series C funding, with the investment led by Vista Credit Partners, a subsidiary of Vista Equity Partners and a strategic financing partner in the enterprise software, data, and technology markets.
The new funding will be used to drive platform innovation, allowing RapidAI to support more disease states and go-to-market functions. The aim is to accelerate growth in new regions and product verticals, solidifying RapidAI’s position as a global leader in clinical AI solutions for life-threatening diseases.
RapidAI’s AI and workflow technology have set the standard for stroke care, which is the second leading cause of death worldwide. The company’s comprehensive portfolio of stroke solutions includes Rapid NCCT Stroke, the first and only FDA-cleared medical device capable of detecting suspected intracranial hemorrhage and large vessel occlusion from non-contrast CT imaging. This technology provides hospitals, regardless of size and imaging capabilities, greater access to imaging and decision support, catering to a wider population of patients.
In addition to stroke care, RapidAI has expanded into new disease states with FDA-cleared modules for cerebral aneurysm management and the identification and notification of suspected central pulmonary embolism. The company is also actively developing additional modules for other disease states.
RapidAI has achieved significant milestones, including analyzing over 10 million scans on its platform, being published in more than 300 peer-reviewed publications, and being deployed in over 2,200 hospitals across 100+ countries. The company’s technology has also been leveraged in over 25 clinical trials.
Karim Karti, CEO of RapidAI, emphasized the growing demand for the company’s solutions in hospitals, as healthcare professionals seek more efficient ways to support clinical decision-making for better patient outcomes. Vista Credit Partners’ support and expertise will enable RapidAI to further advance its vision and technological innovation, solidify its leadership position, and continue providing cutting-edge clinical AI solutions for life-threatening diseases.
RapidAI’s partnership with Vista Credit Partners aligns well with the latter’s focus on providing flexible capital solutions and operational support to accelerate growth and drive category leadership in the enterprise software space. David Flannery, President of Vista Credit Partners, highlighted the impact RapidAI is making in advancing patient care for life-threatening diseases and expressed excitement about the partnership and helping the company achieve its next phase of growth.
As RapidAI continues to leverage AI and advanced technology to transform patient care coordination and enhance care team visibility, it stands at the forefront of the intersection between AI and patient care, driving better outcomes and saving lives.
